Leerink Partnrs Analysts Cut Earnings Estimates for PureTech Health plc (NASDAQ:PRTC)

PureTech Health plc (NASDAQ:PRTC) – Analysts at Leerink Partnrs cut their FY2024 earnings estimates for PureTech Health in a note issued to investors on Wednesday, August 28th. Leerink Partnrs analyst T. Smith now expects that the company will post earnings of ($3.06) per share for the year, down from their previous forecast of ($2.73). The consensus estimate for PureTech Health’s current full-year earnings is ($3.90) per share. Leerink Partnrs also issued estimates for PureTech Health’s FY2025 earnings at ($2.75) EPS, FY2026 earnings at ($5.59) EPS, FY2027 earnings at ($0.65) EPS and FY2028 earnings at $4.08 EPS.

PureTech Health Trading Down 6.7 %

Shares of PureTech Health stock opened at $21.45 on Monday. PureTech Health has a 52-week low of $17.08 and a 52-week high of $34.00. The company has a 50 day moving average of $22.65 and a 200 day moving average of $25.85.

Hedge Funds Weigh In On PureTech Health

An institutional investor recently bought a new position in PureTech Health stock. AWM Investment Company Inc. bought a new stake in PureTech Health plc (NASDAQ:PRTC) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 6,900 shares of the company’s stock, valued at approximately $197,000. 0.04% of the stock is owned by institutional investors and hedge funds.

PureTech Health Company Profile

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.